<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-036299</identifier>
<setSpec>1130-6343</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Cost-effectiveness analysis of tenofovir versus zidovudine in combination therapy with efavirenz and lamivudine for the treatment of HIV in naive patients</dc:title>
<dc:description xml:lang="en">Objectives: To assess tenofovir + lamivudine + efavirenz versus zidovudine + lamivudine + efavirenz in treatment-naive patients using a cost-effectiveness analysis. Methods: A decision tree was designed. Effectiveness was estimated from clinical trials. Viral load and CD4 cells count were chosen as end points for health outcome. Both healthcare and treatment costs were considered, and univariate sensitivity tests were performed. Results: The regimen including tenofovir would have a yearly cost of &#128; 10,116.61 when effective, and of &#128; 12,140.40 in case of therapeutic failure. The regimen including zidovudine would have a yearly cost of &#128; 7,470.36 when effective, and of &#128; 8,964.90 incase of therapeutic failure. The cost of switching to the regimen with tenofovir represents &#128; 14,765.86 per year per additional patient with non-detectable viral load. After 3 years, the expected yearly cost is &#128; 8,765.83 for the regimen including tenofovir versus &#128; 8,894.36 for the regimen including zidovudine. Conclusion: The regimen including zidovudine is less costly in the short run when compared to the regimen including tenofovir. Both regimens become financially similar when extending the study horizon</dc:description>
<dc:creator>Pujol de la Llave, E</dc:creator>
<dc:creator>Fernández Lisón, L. C</dc:creator>
<dc:creator>Hevia Alonso, A</dc:creator>
<dc:creator>Garrido Martínez, M. T</dc:creator>
<dc:creator>Bocanegra Martín, C</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivos: Evaluar los regímenes en pacientes no pretratados de tenofovir + lamivudina + efavirenz versus zidovudina + lamivudina + efavirenz mediante un estudio coste-eficacia. Métodos: Se diseñó un árbol de decisiones. Se estimó la eficaciaa través de ensayos clínicos. Para valorar la medida sobre los resultados de la salud se consideró la carga viral y los CD4. Se consideraron costes asistenciales y de tratamiento, y se realizó un análisis de sensibilidad univariante. Resultados: El régimen con tenofovir tendría un coste anual, en caso de ser efectivo, de 10.116,61 &#128;, mientras que si existefallo terapéutico el coste sería de 12.140,40 &#128;. El régimen que incluye zidovudina tendría un coste anual de 7.470,36 &#128; en caso de ser efectivo, y un coste de 8.964,90 &#128;, en caso de fallo terapéutico.El coste de pasar al régimen que incluye tenofovir supone 14.765,86 &#128; al año por paciente adicional con carga viral indetectable. En 3 años, el coste anual esperado es de 8.765,83 &#128; para el régimen que incluye tenofovir frente a 8.894,36 &#128; del régimen que incluye zidovudina. Conclusión: El régimen que incluye zidovudina es menos costoso a corto plazo que el que incluye tenofovir. Si ampliamos el horizonte del estudio, los dos regímenes se equiparan económicamente</dc:description>
<dc:source>Farm Hosp;29(1): 11-17, ene.-feb. 2005. tab, graf</dc:source>
<dc:identifier>ibc-036299</dc:identifier>
<dc:title xml:lang="es">Análisis coste-eficacia de tenofovir versus zidovudina en terapia combinada con efavirenz y lamivudina para el tratamiento de VIH en pacientes no pretratados</dc:title>
<dc:subject>^d29416^s22011</dc:subject>
<dc:subject>^d38332</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d38332^s22000</dc:subject>
<dc:subject>^d23867</dc:subject>
<dc:subject>^d38332^s22065</dc:subject>
<dc:subject>^d38332^s22020</dc:subject>
<dc:subject>^d16645</dc:subject>
<dc:subject>^d23867^s22020</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23867^s22000</dc:subject>
<dc:subject>^d33123^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>200502</dc:date>
</metadata>
</record>
</ibecs-document>
